Status:

COMPLETED

Pericoital Oral Contraception With Levonorgestrel

Lead Sponsor:

FHI 360

Conditions:

Healthy

Eligibility:

FEMALE

Up to 45 years

Phase:

PHASE3

Brief Summary

A prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel

Detailed Description

This is a prospective, open-label, single arm, multicenter study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel (LNG). The objectives of the study ...

Eligibility Criteria

Inclusion

  • Each woman enrolled in the trial must meet the following inclusion criteria:
  • Competent to provide informed consent to participate in the trial and has done so.
  • At least the minimum age is 18 to 45 years old.
  • Had sex 1 to 4 days in past month and expects to continue at that frequency for the next 6.5 months.
  • At low risk for sexually transmitted infection (STI), operationally meaning that neither she nor her partner to her knowledge has had any of the following:
  • More than one sexual partner currently or any expectation of having more than one sexual partner in the next 6.5 months
  • Diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
  • Treatment for a STI within the past 6 months, excluding recurrent genital herpes or condyloma
  • Sharing of illicit injection drug equipment ever in the past.
  • Willing to use the study regimen as her only contraceptive method for the next 6.5 months (except that she may also use condoms if needed for protection from STIs).
  • Wants to avoid pregnancy for at least the next 6.5 months.
  • Willing to accept an uncertain risk of pregnancy during the study.
  • Gives correct answers to the informed consent quiz.
  • Willing and able to follow all study requirements.

Exclusion

  • To be eligible for enrollment, a woman must not meet any of the following exclusion criteria:
  • Pregnant as verified by a pregnancy test at enrollment.
  • Has an indication of current subfecundity, specifically:
  • Her last pregnancy ended within the last 8 weeks, or she has had fewer than two menstrual periods since resolution of last pregnancy
  • She has not had normal monthly menses for the past 2 months
  • She is currently breastfeeding
  • She has used any hormonal contraceptive other than emergency contraceptive pills since the onset of her last menstrual period
  • Has received an injection of a long term injectable contraceptive in the last 9 months
  • Currently has an intrauterine device
  • Has had a sterilization procedure or ectopic pregnancy
  • Has been diagnosed by a clinician as having a fertility problem
  • Her partner has had a sterilization procedure or infertility diagnosis, to her knowledge.
  • She currently has known contraindications to progestin-only pills, specifically including the following conditions:
  • Unexplained abnormal vaginal bleeding
  • Deep venous thrombosis or pulmonary embolus
  • Active viral hepatitis
  • Decompensated cirrhosis
  • Liver tumor
  • History of breast cancer within the past 5 years.
  • Has a breast mass on examination.
  • Has a personal or family history suggestive of predisposition to thrombosis.
  • Has a serious contraindication to pregnancy (medical condition or use of chronic medication such as isotretinoin or thalidomide).
  • Taking drugs that are known to interact with progestins (such as rifampicin or anticonvulsant medications).
  • Has previously participated in this study.
  • Currently participating in another medical research study.
  • The site investigator or designee perceives another reason to exclude her from the trial.

Key Trial Info

Start Date :

January 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2010

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00922233

Start Date

January 1 2010

End Date

November 1 2010

Last Update

October 29 2013

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Planned Parenthood of the Rocky Mountains

Denver, Colorado, United States, 80232

2

Planned Parenthood Gulf Coast, Inc.

Houston, Texas, United States, 77004

3

Planned Parenthood Association of Utah

Salt Lake City, Utah, United States, 84102

4

CEMICAMP

Campinas, Campinas, Brazil